Seguir
Doug Marchion
Doug Marchion
Research Scientist, Moffitt Cancer Center
Dirección de correo verificada de moffitt.org
Título
Citado por
Citado por
Año
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
P Münster, D Marchion, E Bicaku, M Schmitt, JH Lee, R DeConti, ...
Journal of Clinical Oncology 25 (15), 1979-1985, 2007
2662007
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
DC Marchion, E Bicaku, AI Daud, DM Sullivan, PN Munster
Cancer research 65 (9), 3815-3822, 2005
2482005
ABCG2 expression, function, and promoter methylation in human multiple myeloma
JG Turner, JL Gump, C Zhang, JM Cook, D Marchion, L Hazlehurst, ...
Blood 108 (12), 3881-3889, 2006
2412006
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway
PN Münster, DC Marchion, AD Basso, N Rosen
Cancer research 62 (11), 3132-3137, 2002
2152002
Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
DC Marchion, E Bicaku, AI Daud, V Richon, DM Sullivan, PN Munster
Journal of cellular biochemistry 92 (2), 223-237, 2004
2102004
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
PN Munster, D Marchion, S Thomas, M Egorin, S Minton, G Springett, ...
British journal of cancer 101 (7), 1044-1050, 2009
1892009
Development of histone deacetylase inhibitors for cancer treatment
D Marchion, P Münster
Expert review of anticancer therapy 7 (4), 583-598, 2007
1882007
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC
P Munster, D Marchion, E Bicaku, M Lacevic, J Kim, B Centeno, A Daud, ...
Clinical cancer research 15 (7), 2488-2496, 2009
1762009
IgA transcytosis and antigen recognition govern ovarian cancer immunity
S Biswas, G Mandal, KK Payne, CM Anadon, CD Gatenbee, RA Chaurio, ...
Nature 591 (7850), 464-470, 2021
1262021
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
S Thomas, KT Thurn, E Biçaku, DC Marchion, PN Münster
Breast cancer research and treatment 130, 437-447, 2011
1212011
Selective inhibition of histone deacetylase 2 silences progesterone receptor–mediated signaling
E Biçaku, DC Marchion, ML Schmitt, PN Münster
Cancer research 68 (5), 1513-1519, 2008
1152008
Metabolic vulnerabilities in endometrial cancer
FL Byrne, IKH Poon, SC Modesitt, JL Tomsig, JDY Chow, ME Healy, ...
Cancer research 74 (20), 5832-5845, 2014
1132014
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival
DC Marchion, HM Cottrill, Y Xiong, N Chen, E Bicaku, WJ Fulp, N Bansal, ...
Clinical Cancer Research 17 (19), 6356-6366, 2011
1082011
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
AI Daud, J Dawson, RC DeConti, E Bicaku, D Marchion, S Bastien, ...
Clinical Cancer Research 15 (7), 2479-2487, 2009
1072009
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
DC Marchion, E Bicaku, AI Daud, DM Sullivan, PN Munster
Molecular cancer therapeutics 4 (12), 1993-2000, 2005
1052005
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression
Y Cao, J Trillo-Tinoco, RA Sierra, C Anadon, W Dai, E Mohamed, L Cen, ...
Nature communications 10 (1), 1280, 2019
1002019
BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells
KK Payne, JA Mine, S Biswas, RA Chaurio, A Perales-Puchalt, ...
Science 369 (6506), 942-949, 2020
992020
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition
JG Turner, DC Marchion, JL Dawson, MF Emmons, LA Hazlehurst, ...
Cancer research 69 (17), 6899-6905, 2009
912009
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ
DC Marchion, E Bicaku, JG Turner, AI Daud, DM Sullivan, PN Munster
Clinical cancer research 11 (23), 8467-8475, 2005
742005
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
DC Marchion, E Bicaku, JG Turner, ML Schmitt, DR Morelli, PN Munster
Molecular cancer therapeutics 8 (4), 794-801, 2009
712009
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20